Skip to content
zameds

Codeine, paracetamol (Cetaphos, Panado-co, Paracetacod, Adco Napacod, Zeropyn, Gsa-paracetamol-codeine)

Codeine, paracetamol

Adcock ingram limited

S3Read from the PI-PIL document and verified

Registration

Applicant
Adcock ingram limited
Registrations
6
Schedule source
SAHPRA documentation

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Cetaphos tablets

TABLET CODEINE PHOSPHATE 10 MG PARACETAMOL 500 MG

TabletsB0854B/2.8/854CancelledNot determinedNone
Panado-co tablets

EACH TABLET CONTAINS CODEINE PHOSPHATE 8 mg PARACETAMOL 500 mg

TabletsB1141B/2.8/1141CancelledNot determinedNone
Paracetacod

TABLET CODEINE PHOSPHATE 10 MG PARACETAMOL 500 MG

Not listedB1329B/2.8/1329CancelledNot determinedNone
Adco napacod tablets

TABLET CODEINE PHOSPHATE 10 MG PARACETAMOL 500 MG

10 mg, 500 mgTabletsB1401B/2.8/1401Approved 9 January 2023RegisteredS3PIPIL
Zeropyn

EACH CAPSULE CONTAINS CODEINE PHOSPHATE 10 mg PARACETAMOL 500 mg

Not listedF0155F/2.8/155CancelledNot determinedNone
Gsa-paracetamol-codeine

EACH TABLET CONTAINS CODEINE PHOSPHATE 8 mg PARACETAMOL 500 mg

Not listedN0132N/2.9/132CancelledNot determinedNone

Regulatory status

Where S3 sits on the scale

Needs a doctor's prescription, dispensed by a pharmacist.

Schedule 3 medicines can only be sold on a prescription from an authorised prescriber, such as a doctor or dentist. A pharmacist dispenses the medicine once they have the written prescription, or a verbal instruction from a prescriber they know. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S3, read from the product's PI-PIL leaflet.

The Consolidated Schedules list this ingredient up to S6; the leaflet's S3 applies to this product.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Codeine phosphate, paracetamol

  • S6: Codeine

    • single component codeine preparations;
    • oral solid preparations, in combination with one or more therapeutically active substances, in preparations not registered in terms of the Act, or when intended for export; (S2, S3)
    • liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, in preparations not registered in terms of the Act, or when intended for export. (S2, S3)

    Consolidated Schedules 06 July 2026, lines 10128 to 10136

  • S3: Codeine

    • oral solid preparations, in combination with one or more therapeutically active substances, containing more than 10 milligrams of codeine (calculated as base) per dosage unit, when contained in products registered in terms of the Act, and not intended for export;
    • liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit, when contained in products registered in terms of the Act, and not intended for export;
    • except oral solid preparations, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as base) per dosage unit, with a maximum daily dose not exceeding 80 milligrams, and in packs containing sufficient dosage units for a maximum treatment period of 5 days and limited to one pack per customer, when contained in products registered in terms of the Act, and not intended for export; (S2)
    • except liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit, with a maximum daily dose not exceeding 80 milligrams, and with a pack size not exceeding 100 millilitres and limited to one pack per customer, when contained in products registered in terms of the Act, and not intended for export; (S2)
    • except single component codeine preparations. (S6)

    Consolidated Schedules 06 July 2026, lines 3350 to 3372

  • S3: Paracetamol

    • when intended for injection.

    Consolidated Schedules 06 July 2026, line 4093

  • S2: Codeine

    • oral solid preparations, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as base) per dosage unit, with a maximum daily dose not exceeding 80 milligrams, and in packs containing sufficient dosage units for a maximum treatment period of 5 days, and limited to one pack per customer, when contained in products registered in terms of the Act, and not intended for export;
    • liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit, with a maximum daily dose not exceeding 80 milligrams, and with a pack size not exceeding 100 millilitres, when contained in products registered in terms of the Act, and not intended for export;
    • except oral solid preparations, in combination with one or more therapeutically active substances, containing more than 10 milligrams of codeine (calculated as base) per dosage unit; (S3)
    • except liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit; (S3)
    • except single component codeine preparations. (S6)

    Consolidated Schedules 06 July 2026, lines 1758 to 1778

  • S2: Paracetamol

    • when contained in rectal suppositories, or
    • when contained in modified release formulations. (S0, S1, S3)

    Consolidated Schedules 06 July 2026, lines 2496 to 2500

  • S1: Paracetamol

    • immediate release tablets or capsules each containing 500 milligrams or less of paracetamol, or in individually wrapped powders or in sachets containing 1 000 milligrams or less of paracetamol, subject to - (i) a maximum of 12,5 grams of paracetamol per primary pack, and (ii) in the case of tablets or capsules, presented in blister strip packaging or in containers with child-resistant closures; and (iii) labelled with the following boxed warning, placed prominently on at least the main panel of the immediate container label and outer label (carton): “CONTAINS PARACETAMOL - READ THE PACKAGE INSERT”; (S0)
    • in liquid or syrup dosage form containing 120 milligrams or less of paracetamol per 5 millilitres or in paediatric drops containing 120 milligrams or less of paracetamol per 1,2 millilitres, subject to - (i) a maximum of 100 millilitres per primary pack in the case of the liquid or syrup dosage form containing 120 milligrams or less of paracetamol per 5 millilitres; (ii) a maximum of 20 millilitres per primary pack in the case of the paediatric drops; (iii) labelled with the following boxed warning, placed prominently on at least the main panel of the immediate container label and outer label (carton): “CONTAINS PARACETAMOL - READ THE PACKAGE INSERT”; (S0)
    • when contained in rectal suppositories. (S2)
    • when contained in modified release formulations. (S2)
    • when intended for injection. (S3)

    Consolidated Schedules 06 July 2026, lines 958 to 997

Pharmacological class: Analgesic combinations. (class 2.8)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Combination product

This product contains more than one active ingredient, so it has no single molecular structure.

SAHPRA documents

Schedule verified from official documents

Schedule Verification

This medication's schedule (S3) has been verified from official SAHPRA documents with 90% confidence.

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles